Literature DB >> 21261617

8-Hydroxy-2'-deoxyguanosine is a prognostic mediator for cardiac event.

Satoshi Suzuki1, Tetsuro Shishido, Mitsunori Ishino, Shigehiko Katoh, Toshiki Sasaki, Satoshi Nishiyama, Takehiko Miyashita, Takuya Miyamoto, Joji Nitobe, Tetsu Watanabe, Yasuchika Takeishi, Isao Kubota.   

Abstract

BACKGROUND: DNA in the nucleus is one of the major targets of reactive oxygen species (ROS), and oxidative DNA damage has been implicated in the pathogenesis of chronic heart failure. 8-Hydroxy-2'-deoxyguanosine (8-OHdG) is produced from deoxyguanosine in DNA by ROS. The purpose of this present study was to examine the clinical significance of serum 8-OHdG levels in patients with heart failure.
METHODS: We measured serum 8-OHdG levels in 230 patients with chronic heart failure and 42 control subjects without heart failure by sandwich enzyme-linked immunosorbent assay. Patients were prospectively followed during a median follow-up period of 472 days with the end points of cardiac death or progressive heart failure requiring re-hospitalization.
RESULTS: Serum 8-OHdG concentrations were higher in patients with heart failure than in control subjects (P < 0·001) and increased with advancing New York Heart Association (NYHA) functional class (P < 0·001). Normal upper limit of 8-OHdG level was determined as mean ± 2SD value from 42 control subjects (0·40 ng mL(-1)). Abnormally high serum 8-OHdG levels (> 0·40 ng mL(-1)) were observed in 21·2%, 43·1%, 42·6% and 69·4% through NYHA I to IV (P < 0·001). A total of 66 cardiac events occurred during a follow-up period, and Kaplan-Meier survival curves demonstrated that cardiac event rate was markedly higher in patients with high 8-OHdG levels than in those with normal 8-OHdG levels (62·4% vs. 29·6%, P = 0·0007).
CONCLUSIONS: Serum 8-OHdG levels provide important prognostic information for the risk stratification of patients with heart failure.
© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21261617     DOI: 10.1111/j.1365-2362.2010.02465.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  11 in total

Review 1.  Emerging horizons of salivary diagnostics for periodontal disease.

Authors:  L Fuentes; M Yakob; D T W Wong
Journal:  Br Dent J       Date:  2014-11       Impact factor: 1.626

Review 2.  8-hydroxy-2'-deoxyguanosine and cardiovascular disease: a systematic review.

Authors:  Lona J Kroese; Peter G Scheffer
Journal:  Curr Atheroscler Rep       Date:  2014-11       Impact factor: 5.113

3.  Additive clinical value of serum brain-derived neurotrophic factor for prediction of chronic heart failure outcome.

Authors:  Shinpei Kadowaki; Tetsuro Shishido; Yuki Honda; Taro Narumi; Yoichiro Otaki; Daisuke Kinoshita; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Takuya Miyamoto; Tetsu Watanabe; Isao Kubota
Journal:  Heart Vessels       Date:  2015-01-24       Impact factor: 2.037

4.  Norepinephrine-induced apoptotic and hypertrophic responses in H9c2 cardiac myoblasts are characterized by different repertoire of reactive oxygen species generation.

Authors:  Anita Thakur; Md Jahangir Alam; M R Ajayakumar; Saroj Ghaskadbi; Manish Sharma; Shyamal K Goswami
Journal:  Redox Biol       Date:  2015-05-29       Impact factor: 11.799

5.  Inhibition of TGF-β by a novel PPAR-γ agonist, chrysin, salvages β-receptor stimulated myocardial injury in rats through MAPKs-dependent mechanism.

Authors:  Neha Rani; Saurabh Bharti; Jagriti Bhatia; Ameesha Tomar; T C Nag; Ruma Ray; Dharamvir Singh Arya
Journal:  Nutr Metab (Lond)       Date:  2015-03-09       Impact factor: 4.169

6.  Relationship between post-cardiac arrest myocardial oxidative stress and myocardial dysfunction in the rat.

Authors:  Fernanda Schäfer Hackenhaar; Francesca Fumagalli; Giovanni Li Volti; Valeria Sorrenti; Ilaria Russo; Lidia Staszewsky; Serge Masson; Roberto Latini; Giuseppe Ristagno
Journal:  J Biomed Sci       Date:  2014-08-19       Impact factor: 8.410

7.  Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial.

Authors:  Satoshi Suzuki; Akiomi Yoshihisa; Tetsuro Yokokawa; Atsushi Kobayashi; Takayoshi Yamaki; Hiroyuki Kunii; Kazuhiko Nakazato; Akihiro Tsuda; Tatsunori Tsuda; Toshiyuki Ishibashi; Ichiro Konno; Osamu Yamaguchi; Hirofumi Machii; Naoki Nozaki; Takeshi Niizeki; Takuya Miyamoto; Yasuchika Takeishi
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

8.  Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure.

Authors:  Akira Funayama; Tetsuro Shishido; Shunsuke Netsu; Taro Narumi; Shinpei Kadowaki; Hiroki Takahashi; Takuya Miyamoto; Tetsu Watanabe; Chang-Hoon Woo; Jun-ichi Abe; Koichiro Kuwahara; Kazuwa Nakao; Yasuchika Takeishi; Isao Kubota
Journal:  Cardiovasc Res       Date:  2013-05-25       Impact factor: 10.787

9.  Relationship Between Plasma 8-OH-Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial.

Authors:  Merlin C Thomas; Mark Woodward; Qiang Li; Raelene Pickering; Christos Tikellis; Neil Poulter; Mark E Cooper; Michel Marre; Sophia Zoungas; John Chalmers
Journal:  J Am Heart Assoc       Date:  2018-06-30       Impact factor: 5.501

Review 10.  Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis.

Authors:  Adam J Causer; Janis K Shute; Michael H Cummings; Anthony I Shepherd; Mathieu Gruet; Joseph T Costello; Stephen Bailey; Martin Lindley; Clare Pearson; Gary Connett; Mark I Allenby; Mary P Carroll; Thomas Daniels; Zoe L Saynor
Journal:  Redox Biol       Date:  2020-01-23       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.